NZ704490A - Glycoconjugation processes and compositions - Google Patents
Glycoconjugation processes and compositionsInfo
- Publication number
- NZ704490A NZ704490A NZ704490A NZ70449013A NZ704490A NZ 704490 A NZ704490 A NZ 704490A NZ 704490 A NZ704490 A NZ 704490A NZ 70449013 A NZ70449013 A NZ 70449013A NZ 704490 A NZ704490 A NZ 704490A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compositions
- glycoconjugation
- processes
- glycoconjugates
- immunogenic compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261684043P | 2012-08-16 | 2012-08-16 | |
| PCT/IB2013/056597 WO2014027302A1 (en) | 2012-08-16 | 2013-08-12 | Glycoconjugation processes and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ704490A true NZ704490A (en) | 2017-07-28 |
Family
ID=49385307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ704490A NZ704490A (en) | 2012-08-16 | 2013-08-12 | Glycoconjugation processes and compositions |
Country Status (32)
| Country | Link |
|---|---|
| US (6) | US9517274B2 (https=) |
| EP (2) | EP2885007B1 (https=) |
| JP (1) | JP6291495B2 (https=) |
| KR (1) | KR101742406B1 (https=) |
| CN (1) | CN104661684B (https=) |
| AR (2) | AR092368A1 (https=) |
| AU (1) | AU2013303826B2 (https=) |
| BR (1) | BR112015003227B1 (https=) |
| CA (1) | CA2881420C (https=) |
| DK (2) | DK2885007T3 (https=) |
| ES (2) | ES2700824T3 (https=) |
| FI (1) | FIC20220032I1 (https=) |
| FR (1) | FR22C1037I2 (https=) |
| HU (3) | HUE049531T2 (https=) |
| IL (1) | IL237066B (https=) |
| IN (1) | IN2015DN00694A (https=) |
| LU (1) | LUC00273I2 (https=) |
| MX (1) | MX363511B (https=) |
| MY (1) | MY167579A (https=) |
| NL (1) | NL301188I2 (https=) |
| NO (1) | NO2022034I1 (https=) |
| NZ (1) | NZ704490A (https=) |
| PE (1) | PE20150464A1 (https=) |
| PH (1) | PH12015500243B1 (https=) |
| PL (2) | PL3421051T3 (https=) |
| PT (2) | PT2885007T (https=) |
| RU (2) | RU2645071C2 (https=) |
| SA (1) | SA515360035B1 (https=) |
| SG (1) | SG11201500566XA (https=) |
| SI (2) | SI2885007T1 (https=) |
| TW (1) | TWI480049B (https=) |
| WO (1) | WO2014027302A1 (https=) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2885007T1 (sl) | 2012-08-16 | 2018-12-31 | Pfizer Inc. | Postopki in kompozicije glikokonjugacij |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN120718167A (zh) | 2014-01-21 | 2025-09-30 | 辉瑞大药厂 | 肺炎链球菌荚膜多糖及其缀合物 |
| IL312327B2 (en) * | 2014-01-21 | 2026-02-01 | Pfizer | Immunogenic preparations comprising conjugated capsular saccharide antigens and their uses |
| BR112016016580B1 (pt) * | 2014-01-21 | 2024-01-09 | Pfizer Inc | Processo para a preparação de um conjugado imunogênico, conjugado imunogênico, composição imunogênica, e vacina |
| EP3104886B1 (en) | 2014-02-14 | 2018-10-17 | Pfizer Inc | Immunogenic glycoprotein conjugates |
| SI3116887T1 (sl) | 2014-03-13 | 2021-06-30 | Universitaet Basel | Ogljikohidratni ligandi, ki se vežejo na protitelesa img proti glikoproteinu, ki je povezan z mielinom |
| CN107427568B (zh) | 2015-01-15 | 2021-12-14 | 辉瑞公司 | 用于肺炎球菌疫苗中的免疫原性组合物 |
| PE20220774A1 (es) * | 2015-05-04 | 2022-05-16 | Pfizer | Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos |
| PE20180460A1 (es) * | 2015-06-08 | 2018-03-06 | Serum Inst Of India Private Ltd | Metodos para mejorar la adsorcion de conjugados de polisacarido-proteina y una formulacion de vacuna multivalente obtenida con los mismos |
| CN108367063A (zh) * | 2015-07-21 | 2018-08-03 | 辉瑞公司 | 包含缀合的荚膜糖抗原的免疫原性组合物及其试剂盒和用途 |
| US11091591B2 (en) | 2015-09-16 | 2021-08-17 | Universität Basel | Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids |
| JP6884145B2 (ja) | 2015-11-20 | 2021-06-09 | ファイザー・インク | 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物 |
| KR102437120B1 (ko) | 2016-08-05 | 2022-08-25 | 사노피 파스퇴르 인코포레이티드 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| JP7001686B2 (ja) | 2016-08-05 | 2022-02-04 | サノフィ パスツール インコーポレイティッド | 多価肺炎球菌多糖体－タンパク質コンジュゲート組成物 |
| KR102906912B1 (ko) | 2016-09-02 | 2026-01-05 | 사노피 파스퇴르 인크 | 네이세리아 메닌기티디스 백신 |
| ES3024474T3 (en) | 2016-12-30 | 2025-06-04 | Vaxcyte Inc | Polypeptide-antigen conjugates with non-natural amino acids |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| US11413344B2 (en) | 2017-01-20 | 2022-08-16 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
| MX2019014829A (es) | 2017-06-10 | 2020-08-17 | Inventprise Llc | Vacunas de conjugado multivalente con polisacáridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas. |
| EP3678655A4 (en) | 2017-09-07 | 2021-05-05 | Merck Sharp & Dohme Corp. | PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC POLYSACCHARIDE CARRIER PROTEIN CONJUGATES |
| AU2018328040B2 (en) | 2017-09-07 | 2025-01-16 | Merck Sharp & Dohme Llc | Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein |
| KR20230008923A (ko) | 2018-02-05 | 2023-01-16 | 사노피 파스퇴르 인코포레이티드 | 다가 폐렴구균성 다당류-단백질 접합체 조성물 |
| AU2019215212B2 (en) | 2018-02-05 | 2025-05-15 | Sk Bioscience Co., Ltd. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| WO2019178699A1 (en) * | 2018-03-23 | 2019-09-26 | Koranex Capital | Precision glycoconjugates as therapeutic tools |
| JP2021522213A (ja) | 2018-04-18 | 2021-08-30 | エスケー バイオサイエンス カンパニー リミテッド | ストレプトコッカス・ニューモニエ莢膜多糖類及びその免疫原性接合体 |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| JP7239509B6 (ja) | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
| CA3136278A1 (en) | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| CN111024832B (zh) * | 2019-10-29 | 2022-05-03 | 北京成大天和生物科技有限公司 | 多糖结合疫苗中残余NaCNBH3的离子色谱检测方法 |
| CA3159573A1 (en) | 2019-11-01 | 2021-05-06 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| CA3171864A1 (en) | 2020-02-21 | 2021-08-26 | Pfizer Inc. | Purification of saccharides |
| NZ790372A (en) | 2020-02-23 | 2026-01-30 | Pfizer | Escherichia coli compositions and methods thereof |
| WO2022035816A1 (en) | 2020-08-10 | 2022-02-17 | Inventprise, Llc | Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f |
| IL308201A (en) | 2020-09-17 | 2024-01-01 | Janssen Pharmaceuticals Inc | Multivalent vaccine compositions and uses thereof |
| JP2023546446A (ja) | 2020-10-22 | 2023-11-02 | ファイザー・インク | 細菌多糖を精製する方法 |
| MX2023004912A (es) | 2020-10-27 | 2023-05-16 | Pfizer | Composiciones de escherichia coli y metodos de las mismas. |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| KR20230097160A (ko) | 2020-11-04 | 2023-06-30 | 화이자 인코포레이티드 | 폐렴구균 백신에 사용하기 위한 면역원성 조성물 |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| CA3218544A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against bacterial and betacoronavirus infections |
| WO2022234416A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| EP4346893A2 (en) | 2021-05-28 | 2024-04-10 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| MX2023013434A (es) | 2021-05-28 | 2023-12-12 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos. |
| CN116930159A (zh) * | 2022-03-30 | 2023-10-24 | 爱美客技术发展股份有限公司 | 一种表征交联多糖中交联程度的方法 |
| WO2024084397A1 (en) | 2022-10-19 | 2024-04-25 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| JP2025537898A (ja) | 2022-11-22 | 2025-11-20 | ファイザー・インク | コンジュゲートさせた莢膜糖類抗原を含む免疫原性組成物およびその使用 |
| IL321069A (en) | 2022-12-01 | 2025-07-01 | Pfizer | Pneumococcal conjugate vaccine preparations |
| KR20250163977A (ko) | 2023-03-30 | 2025-11-21 | 화이자 인코포레이티드 | 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도 |
| EP4694921A1 (en) | 2023-04-14 | 2026-02-18 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| EP4701656A1 (en) | 2023-04-24 | 2026-03-04 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024241172A2 (en) | 2023-05-19 | 2024-11-28 | Glaxosmithkline Biologicals Sa | Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection |
| WO2025057078A1 (en) | 2023-09-14 | 2025-03-20 | Pfizer Inc. | Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof |
| WO2025186705A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| TW202602467A (zh) | 2024-03-11 | 2026-01-16 | 美商輝瑞股份有限公司 | 包含經共軛之大腸桿菌糖的免疫原性組成物及其用途 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US578573A (en) | 1897-03-09 | Brake-actuating mechanism | ||
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| IL101715A (en) | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
| US5769047A (en) | 1991-12-23 | 1998-06-23 | Zoche; Michael | Engine with oil separator |
| DK0616034T3 (da) | 1993-03-05 | 2005-02-21 | Wyeth Corp | Plasmid til fremstilling af CRM-protein og diphtheria toxin |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| WO1998056942A1 (en) | 1997-06-12 | 1998-12-17 | Shin-Etsu Bio, Inc. | Production of non-native bacterial exopolysaccharide in a recombinant bacterial host |
| ATE378066T1 (de) | 1998-09-30 | 2007-11-15 | Wyeth Corp | Mutiertes cholera holotoxin als hilfsmittel |
| US6936258B1 (en) | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
| DE19926475A1 (de) * | 1999-06-10 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Träger-Pharmaka-Konjugate |
| OA12590A (en) * | 2001-01-23 | 2006-06-08 | Aventis Pasteur | Multivalent meningococcal polysaccharide-protein conjugate vaccine. |
| KR100898648B1 (ko) | 2001-06-07 | 2009-05-22 | 와이어쓰 홀딩스 코포레이션 | 보조제로서 콜레라 홀로톡신의 돌연변이체 형태 |
| CA2449670A1 (en) | 2001-06-07 | 2002-12-12 | Wyeth Holdings Corporation | Mutant forms of cholera holotoxin as an adjuvant |
| CN1394867A (zh) * | 2001-07-06 | 2003-02-05 | 中国科学院生态环境研究中心 | 可作药物的寡糖和其制备方法及含该寡糖的药物组合物 |
| AU2003277139A1 (en) * | 2002-10-03 | 2004-04-23 | Wyeth Holdings Corporation | Process for preparing monoprotected diols from symmetric diols |
| BRPI0408167B1 (pt) | 2003-03-07 | 2014-10-21 | Wyeth Corp | Conjugados de polissacarídeo-proteína veículo adesina da superfície estafilocócica para imunização contra infecções nosocomiais |
| US20060251675A1 (en) | 2003-03-17 | 2006-11-09 | Michael Hagen | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| AU2005238432A1 (en) * | 2004-04-14 | 2005-11-10 | Wyeth | Process for preparing rapamycin 42-esters and FK-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies |
| US7910753B2 (en) * | 2004-09-10 | 2011-03-22 | Anaspec Incorporated | Cyanine dyes and their applications as luminescence quenching compounds |
| CA2604363C (en) | 2005-04-08 | 2015-06-16 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| GB0513069D0 (en) * | 2005-06-27 | 2005-08-03 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| PL1973564T3 (pl) * | 2005-12-22 | 2017-04-28 | Glaxosmithkline Biologicals S.A. | Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae |
| TW200806685A (en) * | 2006-02-21 | 2008-02-01 | Wyeth Corp | Processes for the convergent synthesis of calicheamicin derivatives |
| MX2008011458A (es) * | 2006-03-07 | 2008-09-24 | Wyeth Corp | Procedimiento para preparar conjugados de polietilenglicol solubles en agua de inmunosupresores de macrolidos. |
| WO2007127668A2 (en) | 2006-04-26 | 2007-11-08 | Wyeth | Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations |
| DE102006026436A1 (de) * | 2006-06-07 | 2007-12-13 | Continental Aktiengesellschaft | Verfahren und Messfahrzeug zur Ermittlung objektiver Reifeneigenschaften auf einer Fahrbahnoberfläche |
| EP2170391B1 (en) * | 2007-06-20 | 2017-01-18 | Pfizer Ireland Pharmaceuticals | Modified polysaccharides for conjugate vaccines |
| RU2378015C2 (ru) * | 2008-04-02 | 2010-01-10 | Равшан Иноятович Атауллаханов | Конъюгат для иммунизации и вакцинации и способ повышения иммуногенности |
| BRPI1011753B8 (pt) | 2009-06-22 | 2021-05-25 | Wyeth Llc | conjugados imunogênicos de polissacarídeo capsular de staphylococcus aureus de sorotipos 5 e 8, seu uso e composições que os compreendem |
| ES2576853T3 (es) * | 2009-07-03 | 2016-07-11 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Compuestos dirigidos al receptor del manosa 6-fosfato independiente de cationes |
| PT2503995T (pt) * | 2009-11-24 | 2017-11-23 | Grifols Therapeutics Inc | Métodos de liofilização, composições e kits |
| AR084158A1 (es) * | 2010-12-10 | 2013-04-24 | Merck Sharp & Dohme | Formulaciones que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas |
| KR102109067B1 (ko) * | 2011-09-07 | 2020-05-13 | 프로린크스 엘엘시 | 생분해성 교차결합을 가지는 하이드로젤 |
| SI2885007T1 (sl) | 2012-08-16 | 2018-12-31 | Pfizer Inc. | Postopki in kompozicije glikokonjugacij |
| IL312327B2 (en) | 2014-01-21 | 2026-02-01 | Pfizer | Immunogenic preparations comprising conjugated capsular saccharide antigens and their uses |
| EP3104886B1 (en) | 2014-02-14 | 2018-10-17 | Pfizer Inc | Immunogenic glycoprotein conjugates |
-
2013
- 2013-08-12 SI SI201331242T patent/SI2885007T1/sl unknown
- 2013-08-12 HU HUE18183661A patent/HUE049531T2/hu unknown
- 2013-08-12 EP EP13779365.9A patent/EP2885007B1/en active Active
- 2013-08-12 AU AU2013303826A patent/AU2013303826B2/en active Active
- 2013-08-12 PL PL18183661T patent/PL3421051T3/pl unknown
- 2013-08-12 PL PL13779365T patent/PL2885007T3/pl unknown
- 2013-08-12 PT PT13779365T patent/PT2885007T/pt unknown
- 2013-08-12 SI SI201331739T patent/SI3421051T1/sl unknown
- 2013-08-12 IN IN694DEN2015 patent/IN2015DN00694A/en unknown
- 2013-08-12 US US14/420,822 patent/US9517274B2/en active Active
- 2013-08-12 RU RU2015103017A patent/RU2645071C2/ru active
- 2013-08-12 EP EP18183661.0A patent/EP3421051B1/en active Active
- 2013-08-12 JP JP2015527054A patent/JP6291495B2/ja active Active
- 2013-08-12 CA CA2881420A patent/CA2881420C/en active Active
- 2013-08-12 PE PE2015000211A patent/PE20150464A1/es active IP Right Grant
- 2013-08-12 KR KR1020157006296A patent/KR101742406B1/ko active Active
- 2013-08-12 NZ NZ704490A patent/NZ704490A/en unknown
- 2013-08-12 SG SG11201500566XA patent/SG11201500566XA/en unknown
- 2013-08-12 DK DK13779365.9T patent/DK2885007T3/en active
- 2013-08-12 RU RU2016136630A patent/RU2724840C2/ru active
- 2013-08-12 WO PCT/IB2013/056597 patent/WO2014027302A1/en not_active Ceased
- 2013-08-12 HU HUE13779365A patent/HUE041381T2/hu unknown
- 2013-08-12 MY MYPI2015700444A patent/MY167579A/en unknown
- 2013-08-12 ES ES13779365T patent/ES2700824T3/es active Active
- 2013-08-12 CN CN201380049088.XA patent/CN104661684B/zh active Active
- 2013-08-12 DK DK18183661.0T patent/DK3421051T3/da active
- 2013-08-12 MX MX2015001992A patent/MX363511B/es unknown
- 2013-08-12 BR BR112015003227-3A patent/BR112015003227B1/pt active IP Right Grant
- 2013-08-12 PT PT181836610T patent/PT3421051T/pt unknown
- 2013-08-12 ES ES18183661T patent/ES2800479T3/es active Active
- 2013-08-15 TW TW102129348A patent/TWI480049B/zh active
- 2013-08-15 AR ARP130102904A patent/AR092368A1/es active IP Right Grant
-
2015
- 2015-02-02 IL IL237066A patent/IL237066B/en active IP Right Grant
- 2015-02-04 PH PH12015500243A patent/PH12015500243B1/en unknown
- 2015-02-15 SA SA515360035A patent/SA515360035B1/ar unknown
-
2016
- 2016-11-09 US US15/347,034 patent/US9950054B2/en active Active
-
2018
- 2018-04-05 US US15/946,664 patent/US10583187B2/en active Active
-
2020
- 2020-01-28 US US16/774,309 patent/US11110160B2/en active Active
-
2021
- 2021-08-05 US US17/395,108 patent/US11723965B2/en active Active
-
2022
- 2022-07-22 LU LU00273C patent/LUC00273I2/fr unknown
- 2022-07-25 NL NL301188C patent/NL301188I2/nl unknown
- 2022-07-28 HU HUS2200034C patent/HUS2200034I1/hu unknown
- 2022-07-28 FR FR22C1037C patent/FR22C1037I2/fr active Active
- 2022-08-04 NO NO2022034C patent/NO2022034I1/no unknown
- 2022-08-05 FI FIC20220032C patent/FIC20220032I1/fi unknown
-
2023
- 2023-06-21 US US18/338,961 patent/US12447203B2/en active Active
-
2024
- 2024-10-28 AR ARP240102937A patent/AR134188A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015500243A1 (en) | Glycoconjugation processes and compositions | |
| MX340090B (es) | Analogos de spliceostatina. | |
| MY170719A (en) | Antibody-drug conjugates | |
| MX350200B (es) | Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74. | |
| PH12015501000A1 (en) | Anti-notch3 antibodies and antibody-drug conjugates | |
| PH12013502192A1 (en) | Antibodies against human angiopoietin 2 | |
| PH12014501039B1 (en) | Cytotoxic peptides and antibody drug conjugates thereof | |
| MX336682B (es) | Anticuerpos contra csf-1r humanos y usos de los mismos. | |
| MY169837A (en) | Immunogenic compositions of staphylococcus aureus antigens | |
| GB201101665D0 (en) | Immunogenic compositions | |
| MX2015002482A (es) | Composicion inmunogenica. | |
| NZ703581A (en) | Anti-cd70 antibody drug conjugates | |
| MX2015000314A (es) | Anticuerpos anti-cd79b e inmunoconjugados. | |
| UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
| MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
| WO2014163714A3 (en) | Antibody drug conjugates | |
| MA35816B1 (fr) | Dérivés d'aniline, leur préparation et leur application thérapeutique | |
| MX2019008773A (es) | Derivados de caliqueamicina y conjugados anticuerpo-farmaco de los mismos. | |
| MX2015004258A (es) | Uso de una membrana de intercambio iónico para retirar impurezas de conjugados de agentes de unión celular y agentes. | |
| EP4321218A3 (en) | Cancer stem cell targeted cancer vaccines | |
| WO2012061012A3 (en) | 4-amino-2h-pyran-2-one analogs as anticancer agents | |
| PH12018500014A1 (en) | Total synthesis of shishijimicin a and analogs thereof | |
| TR200904500A2 (tr) | Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları. | |
| IN2013DE03665A (https=) | ||
| BR112013023599A2 (pt) | método para preparar um conjugado de carboidrato-epítopo de célula-t, conjugado de carboidrato-epítopo de célula-t, e, uso de um conjugado de carboidrato-epítopo de célula-t |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 AUG 2019 BY THOMSON REUTERS Effective date: 20180721 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 AUG 2020 BY THOMSON REUTERS Effective date: 20190725 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 AUG 2021 BY THOMSON REUTERS Effective date: 20200721 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 AUG 2022 BY THOMSON REUTERS Effective date: 20210701 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 AUG 2023 BY THOMSON REUTERS Effective date: 20220704 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 AUG 2024 BY THOMSON REUTERS Effective date: 20230703 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 AUG 2025 BY THOMSON REUTERS Effective date: 20240702 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 AUG 2026 BY THOMSON REUTERS Effective date: 20250701 |